Merck & Co. Files First IRA Suit, Signaling Industry Is Ready To Fight
Executive Summary
Coming less than three months before the statutory deadline for CMS to publish the initial list of drugs, Merck’s lawsuit calls US Medicare drug price negotiations ‘extortion’ in a complaint that could be the first of more legal pushback to follow.
You may also be interested in...
First Round Of Drugs Up For Medicare Negotiation Gets Soft Landing
Big pharma valuations mostly held steady as CMS released its list of the first 10 drugs subject to Medicare negotiations under the Inflation Reduction Act, which held few surprises and included products nearing the end of their patent lives by the time negotiated pricing takes effect.
Tracking Industry’s Lawsuits Against IRA’s Medicare Price Negotiations
Industry stakeholders have filed various lawsuits against the US government, attempting to slow down or block the implementation of a new Medicare drug price negotiation program. Pink Sheet's new chart tracks the developments.
Tracking Industry’s Lawsuits Against IRA’s Medicare Price Negotiations
Industry stakeholders have filed various lawsuits against the US government, attempting to slow down or block the implementation of a new Medicare drug price negotiation program. Scrip's new chart tracks the developments.